HC Wainwright & Co. maintains Delcath Systems at Buy, raises price target to $36 from $32
HC Wainwright & Co. kept its Buy rating on Delcath Systems and increased its price target to $36 from $32, suggesting a 77.6% upside from the Nov 9 close of $20.27.
How this was made
The 30-second read
Why it matters
Analyst upgrade may trigger short‑term price appreciation but long‑term performance depends on clinical milestones.
Market read
The price target increase provides a modest catalyst for DCTH, offering a potential short‑term trade idea.
What to watch
Potential regulatory or trial delays not addressed in the note.
Background
Delcath Systems is a small-cap biotech focused on hepatic drug delivery technologies.
Ticker impact
HC Wainwright raised Delcath Systems' price target to $36 from $32, implying a 77.6% upside from the recent close.
upward pressure as investors price in the higher target
The new target is 12.5% higher than the prior one and signals improved outlook, likely prompting short‑term buying.
Market effects
May lift sentiment in the biotech/oncology device sector.
Limited to US biotech investors.
Low global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- AnalystHC Wainwright & Co.
Equity research firm that issued the price target upgrade.
- CompanyDelcath Systems
Biotech firm developing liver‑targeted therapies.
